Biomed Industries Presents Phase 3 Programs of NA-931 Alone and Combining With Oral Semaglutide for Obesity at ADA 2026
Biomed Industries Presents Global Phase 3 Programs of NA-931 as Monotherapy and in Combination With Oral Semaglutide for Obesity at ADA 2026 in New Orleans SAN JOSE, CA, UNITED STATES, June 10, 2026 /EINPresswire.com/ -- First-in-class oral …